By Bernard Groen 
As the oncology community prepares for the ESMO 2025 Congress in Berlin, Germany (17–21 October), healthcare professionals (HCPs) are actively discussing key trials, guidelines, and emerging fields such as cardio-oncology. Utilising CREATION Pinpoint®, our in-house social listening technology, we analysed 500+ HCP posts about ESMO 2025 by 300+ verified HCPs on social media to capture sentiment and expectations. This article explores four key themes:
- Enthusiasm for the monarchE’s breast cancer trial results
- Anticipation for bladder cancer management updates
- New NSCLC guidelines
- The growing focus on cardio-oncology
Promising MonarchE trial results
HCPs have been sharing that the monarchE trial has reported promising results, demonstrating that two years of treatment with Eli Lilly’s abemaciclib significantly improves overall survival in patients. This finding is anticipated to be a highlight at the upcoming ESMO 2025 conference, where HCPs anticipate further data will be presented. The enthusiasm surrounding this trial underscores the ongoing advancements in breast cancer treatment and the potential for new standards of care to emerge from these findings, reflecting the evolving landscape of oncology. Medical oncologist, Dr Yakup Ergün (@dr_yakupergun), shared his excitement about these results and is anticipating more details and reflections from colleagues during ESMO 2025.
Great news!
The monarchE trial announced that two years of abemaciclib demonstrated a significant OS benefit✨️I am looking forward to seeing the data. May be #ESMO25 https://t.co/TzJu4jdDu2
— Yakup Ergün (@dr_yakupergun) August 27, 2025
Bladder cancer management at ESMO
In the run-up to ESMO 2025 one of the topics that is generating significant interest in online HCP discussions is bladder cancer. Particularly regarding the perioperative management of bladder cancer, with trials such as Genentech-sponsored IMvigor011 and Merck (MSD)-sponsored EV303 expected to be discussed. These studies are anticipated to provide insights into new treatment protocols and their implications for clinical practice. The excitement surrounding these presentations highlights the importance of ongoing research in improving outcomes for bladder cancer patients and the role of conferences in disseminating critical findings to the oncology community. Dr Enrique Grande (@drenriquegrande), Head of the Medical Oncology Service at MD Anderson Cancer Center in Madrid, posted about his excitement building up to ESMO 2025, specifically focusing on the bladder cancer track.
How exciting #ESMO25 looks like in thge perioperative management of #bladdercancer 🥰🥰🥰@myESMO #IMvigor011 #EV303 … and more to come!!!!! pic.twitter.com/qp5iA5uWq4
— Enrique Grande (@drenriquegrande) August 18, 2025
Updated NSCLC guidelines released
The ESMO 2025 guidelines for early and locally advanced non-small cell lung cancer (NSCLC) have been released, emphasising the integration of immunotherapy and targeted therapies into treatment protocols. These guidelines outline clear pathways for staging and biomarker testing, reflecting the rapid evolution of treatment options in this field. The incorporation of multidisciplinary discussions into patient management is also highlighted, showcasing a shift towards more personalised and effective treatment strategies for NSCLC patients. Indeed, Dr Rishabh Jain (@DrRishabhOnco), an Interventional Radiologist practising in New Delhi, India, provided detailed updates on the biomarker testing and set the scene up well for the ESMO 2025 track on NSCLC and the debate that will inevitably spark more scientific discussions during the relevant sessions.
🎯 Targeted. 💉 Immune. 🔬 Precise.
The new face of early NSCLC — ESMO 2025 ⚡🔑 Key updates
🧬 Biomarker testing (EGFR, ALK, PD-L1) now mandatory in stage IB–III
💊 Adjuvant targeted therapy
ADAURA → Osimertinib (EGFR)
ALINA → Alectinib (ALK)💉 Peri-op immunotherapy… pic.twitter.com/GHt8r30Bcw
— Dr Rishabh Jain (@DrRishabhOnco) August 28, 2025
Focus on Cardio-Oncology at ESMO
The upcoming ESMO 2025 conference will feature a range of sessions focused on the intersection of oncology and cardiovascular health, particularly in the context of targeted cancer therapies. Experts will discuss the importance of baseline cardiovascular risk assessments and the potential for biomarkers like troponin to predict complications, as Dr Novi Yanti Sari (@slumberbell), a heart failure cardiologist from Indonesia, shared relating the shared interest between oncology and cardiovascular health in patients, in a post related to ESC 2025 in Madrid.
Earlier this month, CREATION.co attended ESC in Madrid to engage with HCPs as they discussed the latest science in cardiology. ur summary is available in this article: What pharma can learn from HCPs at ESC 2025. HCPs’ focus on cardio-oncology as they prepare for ESMO 2025 reflects a growing recognition of the need to address cardiovascular health in cancer patients, ensuring comprehensive care that considers both cancer treatment and heart health.
Can we predict cardiovascular complications in targeted cancer therapy?🫀
Prof @E_de_Azambuja shares some of the clinical pearls at the #ESCCongress joint session with @myESMO:
📍Baseline CV risk assessment is essential
📍Different patients & treatments = different CV risk… pic.twitter.com/sOqD1HuWtW— Novi Yanti Sari (@slumberbell) August 31, 2025
Key takeaways
The oncology community is approaching ESMO 2025 with high expectations across multiple therapeutic areas. From landmark trial data to updated guidelines and the growing recognition of cardio-oncology, this year’s Congress is poised to spark influential conversations and potentially set new standards of care.
If you’d like to harness insights like these, from granular trial anticipation to emerging clinical themes, our platform CREATION Pinpoint offers end-to-end social intelligence capabilities specifically designed for pharmaceutical leaders. We transform HCP conversation into scalable, strategic intelligence, helping you:
- Prioritise your content and channel activation before, during and after congresses like ESMO 2025.
- Rapidly deploy post-congress insights that convert HCP signals into behaviour-shaping assets.
- Track how momentum shifts across themes and therapy areas with near-real-time dashboards and alerts.
- See how your key medical/clinical contacts perform on our unique CREATION Pinpoint impact score, using our DOL Finder platform.
To explore how this applies to your therapeutic area or upcoming congress planning, get in touch with us anytime. We’d be delighted to tailor a demo or overview that aligns with your business goals.
